Pecfusituzumab
|
WikiDoc Resources for Pecfusituzumab |
|
Articles |
|---|
|
Most recent articles on Pecfusituzumab Most cited articles on Pecfusituzumab |
|
Media |
|
Powerpoint slides on Pecfusituzumab |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pecfusituzumab at Clinical Trials.gov Trial results on Pecfusituzumab Clinical Trials on Pecfusituzumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pecfusituzumab NICE Guidance on Pecfusituzumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pecfusituzumab Discussion groups on Pecfusituzumab Patient Handouts on Pecfusituzumab Directions to Hospitals Treating Pecfusituzumab Risk calculators and risk factors for Pecfusituzumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pecfusituzumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Pecfusituzumab is a humanized monoclonal antibody used to treat cancers of the epithelial origin. It binds to interleukin-2.
Template:Humanizedmonoclonals Template:WH Template:WikiDoc Sources